SUBSCRIBE
SUBSCRIBE

Elicio Therapeutics

IN THE PRESS
Press Releases
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
October 28, 2025
 · 
9 min read
Press Releases
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
September 30, 2025
 · 
9 min read
Press Releases
Elicio Therapeutics Reports Inducement Grants - September 18, 2025
September 18, 2025
 · 
2 min read
Press Releases
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
September 18, 2025
 · 
11 min read
Press Releases
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
August 13, 2025
 · 
11 min read
Press Releases
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 8, 2025
 · 
11 min read
Press Releases
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
August 6, 2025
 · 
10 min read
Press Releases
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
June 17, 2025
 · 
10 min read
Press Releases
Elicio Therapeutics Secures $10 Million in Financing
June 4, 2025
 · 
9 min read
Press Releases
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 14, 2025
 · 
11 min read
Load More
JOBS